Fountain Healthcare Partners III closes on €125m

The fund was launched last year and held a €118m first close in May 2019.

"Life sciences continues to be one of the most attractive sectors for investors," said Aidan King, Fountain managing partner. "Fountain has demonstrated the ability to identify companies in this sector that are developing transformative therapeutics and devices to address unmet medical needs and in doing so to generate attractive investment returns."

This closing brings Fountain's total capital under management to €300m.

Founded in 2008, Fountain is a life sciences venture capital firm with offices in Dublin and New York. The firm invests in entrepreneurs and companies with disruptive technologies or products that have a clear pharmacoeconomic benefit, and a defined pathway to commercialisation, value enhancement and exit.

Fountain typically leads or co-leads its investments, and has sourced private and public deals from startups, corporate spin-outs and turnaround situations.

Investors
The fund raised its capital from local and international institutional investors, including funds-of-funds, sovereign funds and family offices. Its LP base also includes some large corporations such as Japan-based pharmaceutical and biotechnology company Kyowa Kirin.

Investments
Fountain Healthcare Partners III is dedicated to investments across the life sciences sector, with a focus on therapeutics and medical devices.

Fountain Healthcare Partners III will invest a majority of its capital across Europe, but expects to also make investments in the US market.

It plans to complete up to 10 investments and has already completed three deals: Mainstay Medical, a company developing a neuromodulation device to treat chronic lower back pain; Inotrem, a biotechnology company focused on innate immunity; and Priothera, which is developing a drug to reduce relapse and mortality rates in leukemia patients undergoing stem cell transplants.

People
Fountain Healthcare Partners – Manus Rogan, Aidan King (co-founders, managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Ireland
• United States